Transvaginal hydrolaparoscopy to screen for ovarian cancer in high-risk patients

We conducted the present study to determine the outcome of patients with early ovarian cancer who underwent three courses of adjuvant chemotherapy after complete surgical staging. One hundred consecutive patients with stage I–II epithelial ovarian cancer who had undergone complete surgical staging and received three courses of platinum-based chemotherapy were entered in this study. Twenty-one patients were low risk, defined as stage IA–B, grade 1 and histologic types except for clear cell adenocarcinoma, and remaining 79 were high risk. All patients with stage IA or IB, whatever histologic type and histopathologic grade, were alive without disease. The 5-year survival rate was 89.4% for patients with stage IC and 76.2% for those with stage II. The 5-year survival rate for low- and high-risk patients was 100% and 89.4%, respectively. The survival rate for grade 1 was significantly better than that for grade 2 or 3. Multivariate analysis revealed that histologic grade was an independent prognostic factor in stage IC–II ovarian cancer. The outcome of patients with early ovarian cancer undergoing three courses of chemotherapy after complete surgical staging was favorable even in high-risk patients

Download Full-text

Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer

European Journal of Cancer Prevention ◽

10.1097/00008469-200512000-00003 ◽

2005 ◽

Vol 14 (6) ◽

pp. 503-511 ◽

Cited By ~ 9

Author(s):

Michael Patrick Lux ◽

Sven Ackermann ◽

Mayada R. Bani ◽

Caroline Nestle-Krämling ◽

Timm O. Goecke ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Cancer Detection ◽

Early Cancer ◽

Low Risk ◽

Early Cancer Detection ◽

Breast And Ovarian Cancer ◽

High Risk Patients ◽

Risk Patients

Download Full-text

Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

Oncology Letters ◽

10.3892/ol.2016.4533 ◽

2016 ◽

Vol 11 (6) ◽

pp. 3967-3974 ◽

Cited By ~ 9

Author(s):

KARINA DAHL STEFFENSEN ◽

MARIANNE WALDSTRØM ◽

IVAN BRANDSLUND ◽

BENTE LUND ◽

SARAH MEJER SØRENSEN ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Human Epididymis Protein 4 ◽

High Risk Patients ◽

Human Epididymis ◽

Risk Patients

Download Full-text

RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families

Cancer Biomarkers ◽

10.3233/cbm-150519 ◽

2015 ◽

Vol 15 (6) ◽

pp. 775-781 ◽

Cited By ~ 3

Author(s):

Ana Krivokuca ◽

Kira Yanowski ◽

Jelena Rakobradovic ◽

Javier Benitez ◽

Mirjana Brankovic-Magic

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Mutation Screening ◽

High Risk Patients ◽

Hereditary Breast Ovarian Cancer ◽

Risk Patients

Download Full-text

Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis

Frontiers in Immunology ◽

10.3389/fimmu.2021.645839 ◽

2021 ◽

Vol 12 ◽

Author(s):

Xingyu Chen ◽

Hua Lan ◽

Dong He ◽

Runshi Xu ◽

Yao Zhang ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Poor Prognosis ◽

Cox Regression ◽

Risk Group ◽

High Risk Group ◽

Low Risk ◽

Cancer Prognosis ◽

High Risk Patients ◽

Risk Patients

BackgroundOvarian cancer (OC) has the highest mortality rate among gynecologic malignancy. Hypoxia is a driver of the malignant progression in OC, which results in poor prognosis. We herein aimed to develop a validated model that was based on the hypoxia genes to systematically evaluate its prognosis in tumor immune microenvironment (TIM).ResultsWe identified 395 hypoxia-immune genes using weighted gene co-expression network analysis (WGCNA). We then established a nine hypoxia-related genes risk model using least absolute shrinkage and selection operator (LASSO) Cox regression, which efficiently distinguished high-risk patients from low-risk ones. We found that high-risk patients were significantly related to poor prognosis. The high-risk group showed unique immunosuppressive microenvironment, lower antigen presentation, and higher levels of inhibitory cytokines. There were also significant differences in somatic copy number alterations (SCNAs) and mutations between the high- and low-risk groups, indicating immune escape in the high-risk group. Tumor immune dysfunction and exclusion (TIDE) and SubMap algorithms showed that low-risk patients are significantly responsive to programmed cell death protein-1 (PD-1) inhibitors.ConclusionsIn this study, we highlighted the clinical significance of hypoxia in OC and established a hypoxia-related model for predicting prognosis and providing potential immunotherapy strategies.

Download Full-text

Efficacy of pegylated liposomal doxorubicin (PLD) and oxaliplatin (Ox) in pre-treated advanced epithelial ovarian cancer (EOC) in relation to BRCA status

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.16006 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 16006-16006

Author(s):

M. O. Nicoletto ◽

M. E. Donach ◽

L. Borgato ◽

G. Artioli ◽

S. Zovato ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Performance Status ◽

Pegylated Liposomal Doxorubicin ◽

Clear Correlation ◽

High Risk Population ◽

Brca Mutations ◽

P53 Overexpression ◽

High Risk Patients ◽

Risk Patients

16006 Background: The mechanism of action of PLD+Ox suggests that and carriers of BRCA mutations might have better survival compared to sporadic ovarian cancer even when pre-treated in advanced EOC. Methods: Inclusion criteria: Performance Status<=2, relapse or progression after 1–3 lines of therapy; <=4 prior antiblastic drugs; life expectancy >3 months; LVEF >50%, informed consent. Treatment consisted of 1 hr infusion of PLD 30–35 mg/m2 on day 1 and 70 mg/m2 of Ox in 2 hrs on day 2 for 8 cycles, then 2 cycles of PLD alone. Clinical response was evaluated by CT scan every 3 cycles. Primary endpoints were overall survival and its correlation with BRCA mutations and p53. Results: From June 2000, 63 pre-treated pts with advanced EOC were enrolled. Median age = 62 yrs, range 41–83, (18pts >70 yrs). 17 had known germline BRCA1/2 mutations (10pts) or family history of ovarian cancer (4pts). In this BRCA/high-risk population 15 pts were evaluable for response with ORR=93.3% (8 CR, 6 PR>50%, 1 SD). 139 courses were administered (median = 10 courses/pt). There was 1 episode of G3 toxicity: mucositis; G1–2 toxicity was gastrointestinal (16 episodes), mucositis (11 episodes), neutropenia (9 episodes). Median LVEF showed no significant changes during treatment. There is no clear correlation between OS and amount of Platinum/Taxol administered previously. p53 was analyzed for expression and mutations. Mutations were sought in exons 5, 6, 7 and 8. 5/6 CR evaluable for p53 showed overexpression. p53 overexpression was seen in 9/11 evaluable pts; of these 4/9 also had p53 mutations. 3/4 of these patients obtained a complete response. Median survival from 1st cycle has not been reached; mean survival is 63.6 months vs 24.7 for sporadic EOC (p<.001). Presently 15/17 are alive. The 5-yr survival after first course of therapy is estimated at 82%. BRCA/high-risk patients in PLD-Ox therapy also fared better than counterparts from an historical population (OS from diagnosis 179.4 vs 141.1 months, p=.005). Conclusions: PLD+Ox is well tolerated and highly effective in BRCA/high-risk patients and in p53 positive/mutated pts in this population. This therapy offers low toxicity providing good quality of life. No significant financial relationships to disclose.

Download Full-text

Screening of CHEK2 and TP53 p.R337H germ-line mutations in high-risk patients for hereditary breast and ovarian cancer from northeast of Brazil.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.1539 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 1539-1539

Author(s):

Ivana Lucia Oliveira Nascimento ◽

Gabriela Espirito Santo Felix ◽

Taisa Manuela Bonfim Machado-Lopes ◽

Thais Bomfim ◽

Maura Romeo ◽

...

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

High Risk ◽

Cellular Response ◽

Germ Line ◽

Susceptibility Genes ◽

Breast And Ovarian Cancer ◽

High Risk Patients ◽

High Penetrance ◽

Risk Patients

1539 Background: CHEK2 is a molecular messenger that interacts with a checkpoint network of other susceptibility genes like ATM, BRCA1, TP53, MDM2, Cdc25A and Cdc25C. The mission of these checkpoints is to preserve the genome integrity during the cell division by regulating the cellular response to DNA damages. The TP53 p.R337H germline mutation was studied in patients with Li-Fraumeni Syndrome, breast cancer and Choroid plexus carcinomas in Southern of Brazil, but never in the Northeast. In the hereditary breast cancer the mutation frequencies of susceptibility genes of low penetrance like CHEK2 is 1-10%, while for genes of high penetrance as TP53 is <1%. Thus, the aim of this study was to screening for CHEK2 and TP53 most common germline mutations in high-risk patients for hereditary breast and ovarian cancer (HBOC) from Northeast of Brazil. Methods: It was analyzed 100 high-risk patients for HBOC from Bahia, Brazil. The genomic DNA was extract from peripheral blood. The CHEK2 mutations, c.1100delC, c.444+1G>A and p.I157T, and TP53 p.R337H mutation were genotyped by Allelic Specific-PCR or PCR-RFLP. Results: Most of the subjects had only breast cancer (86.0%), followed by ovarian (7.0%) and both breast and ovarian cancer (7.0%). Among the breast cancer cases the most common histological type was the ductal (71.0%), while among the ovarian cancer cases were the serous (57.14%). The mean age at diagnostic was 42 yrs (± 9.99). Any of the patient presented c.1100delC, c.444+1G>A and p.I157T mutations. But, two have the p.R337H mutation. Conclusions: Though there is the hypothesis that mutations of low penetrance genes, such as CHEK2, are more likely to be found than high penetrance genes, such as TP53, here it was demonstrate that three of most predisposing variants of CHEK2, c.1100delC, c.444+1G>A and p.I157T, do not have major contribution in HBOC in the population studied. While, the p.R337H, though presented in low frequency compared with the Southern of Brazil (Ashton-Prolla et al., 2012), seems to have a significant contribution in HBOC.

Download Full-text